@article {Mu844, author = {Alex Mu and Erica Weinberg and Dwight E. Moulin and Hance Clarke}, title = {Pharmacologic management of chronic neuropathic pain}, volume = {63}, number = {11}, pages = {844--852}, year = {2017}, publisher = {The College of Family Physicians of Canada}, abstract = {Objective To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.Quality of evidence A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.Main message Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.Conclusion Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.}, issn = {0008-350X}, URL = {https://www.cfp.ca/content/63/11/844}, eprint = {https://www.cfp.ca/content/63/11/844.full.pdf}, journal = {Canadian Family Physician} }